0

CMHC PULSE

Cardio Metabolic Health Congress – Official Blog

New “Fingerprint” of Inflammation Identified in Obesity-Associated T2DM

Researchers at Boston University School of Medicine have identified a new “fingerprint” of inflammation that may be able to predict which patients with obesity may also develop type 2 diabetes. Specifically, inflammatory proteins known as Th17 cells, which are associated with autoimmune conditions, were identified as major contributors to inflammation and hyperglycemia. Although research has already shown inflammation promotes obesity-related type 2 diabetes and related complications, anti-inflammatory drugs have had limited success in treatment. Thus, the findings may provide better insight into the relationship between inflammation and obesity-related type 2 diabetes.

Read more on the study published in the journal Obesity  here.

Lixisenatide Proves Safety in ELIXA While Liraglutide Shows Greater HbA1c Reduction Compared with SGLT-2 Inhibitors

CV outcomes data from the ELIXA trial have been published in the New England Journal of Medicine for the as-yet FDA unapproved GLP-1 agonist lixisenatide, and have shown no increase or decrease in the rate of major cardiovascular events in patients with acute coronary syndrome. Read more here.

Meanwhile, findings from a recent meta-analysis have shown that among people with type 2 diabetes the GLP-1 agonist liraglutide provided greater HbA1c reductions compared with SGLT-2 inhibitors. Comprising the meta-analysis were 17 randomized controlled trials that included patients with type 2 diabetes inadequately controlled with metformin alone or in combination with sulfonylurea, DPP-4 inhibitors, or thiazolidinedione. Liraglutide was also associated with an improved likelihood of achieving glycemic goals compared with SGLT-2 inhibitors. Read more from a press release on the meta-analysis here.

References:
Pfeffer MA et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247-2257.

Lorenzi M et al. Liraglutide vs SGLT-2 inhibitors in people with type 2 diabetes: a network meta-analysis. Presented at 23rd World Diabetes Congress, Vancouver, BC, Canada; 30 November – 4 December 2015. Abstract number 0226-P.